PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19354233-3	2009	Initial cycloamidation led to complete epimerization at the C-11 stereocenter due to unique steric constraints in the 12-membered depsipeptide ring.	Depsipeptides	130-142	RNA polymerase III subunit K	Homo sapiens	60-64
18948574-6	2009	Either depsipeptide, given at 0.5 mg/kg every other day for 2 weeks, or daclizumab, given at 100 microg weekly for 4 weeks, inhibited tumor growth as monitored by serum levels of soluble IL-2R-alpha (sIL-2R-alpha) and soluble beta2-microglobulin (beta2mu) (P < .001), and prolonged survival of the leukemia-bearing mice (P < .001) compared with the control group.	Depsipeptides	7-19	interleukin 2 receptor, alpha chain	Mus musculus	187-198
19308286-0	2009	Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.	Depsipeptides	111-123	forkhead box O1	Homo sapiens	15-20
19308286-0	2009	Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.	Depsipeptides	111-123	BCL2 like 11	Homo sapiens	31-34
19308286-0	2009	Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.	Depsipeptides	111-123	histone deacetylase 9	Homo sapiens	81-100
19308286-3	2009	In this study, depsipeptide, a novel HDAC inhibitor, was shown to be able to induce significant apoptotic cell death in human lung cancer cells.	Depsipeptides	15-27	histone deacetylase 9	Homo sapiens	37-41
19308286-4	2009	Further study showed that Bim, a BH3-only proapoptotic protein, was significantly upregulated by depsipeptide in cancer cells, and Bim"s function in depsipeptide-induced apoptosis was confirmed by knockdown of Bim with RNAi.	Depsipeptides	97-109	BCL2 like 11	Homo sapiens	26-29
19308286-5	2009	In addition, we found that depsipeptide-induced expression of Bim was directly dependent on acetylation of forkhead box class O1 (FoxO1) that is catalyzed by cyclic adenosine monophosphate-responsive element-binding protein-binding protein, and indirectly induced by a decreased four-and-a-half LIM-domain protein 2.	Depsipeptides	27-39	BCL2 like 11	Homo sapiens	62-65
19308286-5	2009	In addition, we found that depsipeptide-induced expression of Bim was directly dependent on acetylation of forkhead box class O1 (FoxO1) that is catalyzed by cyclic adenosine monophosphate-responsive element-binding protein-binding protein, and indirectly induced by a decreased four-and-a-half LIM-domain protein 2.	Depsipeptides	27-39	forkhead box O1	Homo sapiens	130-135
19308286-6	2009	Moreover, our results demonstrated that FoxO1 acetylation is required for the depsipeptide-induced activation of Bim and apoptosis, using transfection with a plasmid containing FoxO1 mutated at lysine sites and a luciferase reporter assay.	Depsipeptides	78-90	forkhead box O1	Homo sapiens	40-45
19308286-6	2009	Moreover, our results demonstrated that FoxO1 acetylation is required for the depsipeptide-induced activation of Bim and apoptosis, using transfection with a plasmid containing FoxO1 mutated at lysine sites and a luciferase reporter assay.	Depsipeptides	78-90	BCL2 like 11	Homo sapiens	113-116
19308286-6	2009	Moreover, our results demonstrated that FoxO1 acetylation is required for the depsipeptide-induced activation of Bim and apoptosis, using transfection with a plasmid containing FoxO1 mutated at lysine sites and a luciferase reporter assay.	Depsipeptides	78-90	forkhead box O1	Homo sapiens	177-182
18677478-6	2009	Induction of NY-ESO-1 expression on tumor targets using the demethylating agent 5-aza-2"-deoxycytidine (alone or in combination with the histone deacetylase inhibitor depsipeptide) resulted in enhanced interferon-gamma secretion by the TCR-transduced PBL on culture with treated targets.	Depsipeptides	167-179	cancer/testis antigen 1A	Homo sapiens	13-21
18677478-6	2009	Induction of NY-ESO-1 expression on tumor targets using the demethylating agent 5-aza-2"-deoxycytidine (alone or in combination with the histone deacetylase inhibitor depsipeptide) resulted in enhanced interferon-gamma secretion by the TCR-transduced PBL on culture with treated targets.	Depsipeptides	167-179	interferon gamma	Homo sapiens	202-218
18677478-6	2009	Induction of NY-ESO-1 expression on tumor targets using the demethylating agent 5-aza-2"-deoxycytidine (alone or in combination with the histone deacetylase inhibitor depsipeptide) resulted in enhanced interferon-gamma secretion by the TCR-transduced PBL on culture with treated targets.	Depsipeptides	167-179	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	236-239
18948574-7	2009	Combination of depsipeptide with daclizumab enhanced the antitumor effect, as shown by both sIL-2R-alpha and beta2mu levels and survival of the leukemia-bearing mice, compared with those in the depsipeptide or daclizumab alone groups (P < .001).	Depsipeptides	15-27	beta-2 microglobulin	Mus musculus	109-116
19175352-3	2009	A83586C antitumor cyclodepsipeptides also inhibit E2F-mediated transcription by downregulating E2F1 expression and inducing dephosphorylation of the oncogenic hyperphosphorylated retinoblastoma protein (pRb).	Depsipeptides	18-36	E2F transcription factor 1	Homo sapiens	95-99
19175352-3	2009	A83586C antitumor cyclodepsipeptides also inhibit E2F-mediated transcription by downregulating E2F1 expression and inducing dephosphorylation of the oncogenic hyperphosphorylated retinoblastoma protein (pRb).	Depsipeptides	18-36	RB transcriptional corepressor 1	Homo sapiens	203-206
19200053-0	2009	The changing face of HDAC inhibitor depsipeptide.	Depsipeptides	36-48	histone deacetylase 9	Homo sapiens	21-25
19200053-2	2009	A novel and potent HDAC inhibitor, depsipeptide, also known as FK228 or FR901228, is highly efficient in inhibiting the activity of HDACs even at nanomolar concentrations.	Depsipeptides	35-47	histone deacetylase 9	Homo sapiens	19-23
19014694-5	2008	We observed that the HDAC inhibitors, MS-275, trichostatin-A, phenylbutyrate, LAQ824 and depsipeptide, enhanced the antineoplastic action of 5AZA-CdR on EWS cells.	Depsipeptides	89-101	histone deacetylase 9	Homo sapiens	21-25
18821579-2	2009	Here, we show that the histone deacetylase (HDAC) inhibitor FK228 (depsipeptide) has an antitumor effect on MRT cells both in vitro and in vivo.	Depsipeptides	67-79	histone deacetylase 9	Homo sapiens	23-42
18821579-2	2009	Here, we show that the histone deacetylase (HDAC) inhibitor FK228 (depsipeptide) has an antitumor effect on MRT cells both in vitro and in vivo.	Depsipeptides	67-79	histone deacetylase 9	Homo sapiens	44-48
17200366-10	2007	Moreover, long-term treatment with a low dose of depsipeptide resulted in the induction of differentiation into hypertrophic phenotype, as shown by the increment of the alpha1 chain of type X collagen (COL10A1) expression in chondrosarcoma cells.	Depsipeptides	49-61	collagen, type X, alpha 1	Mus musculus	202-209
18605682-1	2008	The conformational study on N-acetyl- N"-methylamide of l-lactic acid (Ac-Lac-NHMe, the Lac dipeptide) is carried out using ab initio HF and density functional methods with the self-consistent reaction field method to explore its backbone conformational preferences and cis-trans isomerization for the depsipeptide with an ester bond in the gas phase and in solution.	Depsipeptides	302-314	lactase	Homo sapiens	74-77
18605682-1	2008	The conformational study on N-acetyl- N"-methylamide of l-lactic acid (Ac-Lac-NHMe, the Lac dipeptide) is carried out using ab initio HF and density functional methods with the self-consistent reaction field method to explore its backbone conformational preferences and cis-trans isomerization for the depsipeptide with an ester bond in the gas phase and in solution.	Depsipeptides	302-314	lactase	Homo sapiens	88-91
18332107-2	2008	Here, we report that an HDAC inhibitor, depsipeptide, exhibited significant demethylating activity on the promoters of several genes, including p16, SALL3, and GATA4 in human lung cancer cell lines H719 and H23, colon cancer cell line HT-29, and pancreatic cancer cell line PANC1.	Depsipeptides	40-52	cyclin dependent kinase inhibitor 2A	Homo sapiens	144-147
18332107-2	2008	Here, we report that an HDAC inhibitor, depsipeptide, exhibited significant demethylating activity on the promoters of several genes, including p16, SALL3, and GATA4 in human lung cancer cell lines H719 and H23, colon cancer cell line HT-29, and pancreatic cancer cell line PANC1.	Depsipeptides	40-52	spalt like transcription factor 3	Homo sapiens	149-154
18332107-2	2008	Here, we report that an HDAC inhibitor, depsipeptide, exhibited significant demethylating activity on the promoters of several genes, including p16, SALL3, and GATA4 in human lung cancer cell lines H719 and H23, colon cancer cell line HT-29, and pancreatic cancer cell line PANC1.	Depsipeptides	40-52	GATA binding protein 4	Homo sapiens	160-165
18332107-3	2008	Although expression of DNA methyltransferase 1 (DNMT1) was not affected by depsipeptide, a decrease in binding of DNMT1 to the promoter of these genes played a dominant role in depsipeptide-induced demethylation and reactivation.	Depsipeptides	177-189	DNA methyltransferase 1	Homo sapiens	23-46
18332107-3	2008	Although expression of DNA methyltransferase 1 (DNMT1) was not affected by depsipeptide, a decrease in binding of DNMT1 to the promoter of these genes played a dominant role in depsipeptide-induced demethylation and reactivation.	Depsipeptides	177-189	DNA methyltransferase 1	Homo sapiens	114-119
18332107-4	2008	Depsipeptide also suppressed expression of histone methyltransferases G9A and SUV39H1, which in turn resulted in a decrease of di- and trimethylated H3K9 around these genes" promoter.	Depsipeptides	0-12	SUV39H1 histone lysine methyltransferase	Homo sapiens	78-85
18332107-5	2008	Furthermore, both loading of heterochromatin-associated protein 1 (HP1alpha and HP1beta) to methylated H3K9 and binding of DNMT1 to these genes" promoter were significantly reduced in depsipeptide-treated cells.	Depsipeptides	184-196	chromobox 5	Homo sapiens	67-75
18332107-5	2008	Furthermore, both loading of heterochromatin-associated protein 1 (HP1alpha and HP1beta) to methylated H3K9 and binding of DNMT1 to these genes" promoter were significantly reduced in depsipeptide-treated cells.	Depsipeptides	184-196	chromobox 1	Homo sapiens	80-87
18332107-5	2008	Furthermore, both loading of heterochromatin-associated protein 1 (HP1alpha and HP1beta) to methylated H3K9 and binding of DNMT1 to these genes" promoter were significantly reduced in depsipeptide-treated cells.	Depsipeptides	184-196	DNA methyltransferase 1	Homo sapiens	123-128
18067154-0	2008	Conformational change from antiparallel beta-sheet to alpha-helix in a series of depsipeptide, -(Leu-Leu-Lac)(n)-: syntheses, spectroscopic studies, and crystal structures of Boc-Leu-Lac-OEt and Boc-(Leu-Leu-Lac)(n)-OEt (n = 1, 2).	Depsipeptides	81-93	lactase	Homo sapiens	105-108
18067154-0	2008	Conformational change from antiparallel beta-sheet to alpha-helix in a series of depsipeptide, -(Leu-Leu-Lac)(n)-: syntheses, spectroscopic studies, and crystal structures of Boc-Leu-Lac-OEt and Boc-(Leu-Leu-Lac)(n)-OEt (n = 1, 2).	Depsipeptides	81-93	lactase	Homo sapiens	183-186
18067154-0	2008	Conformational change from antiparallel beta-sheet to alpha-helix in a series of depsipeptide, -(Leu-Leu-Lac)(n)-: syntheses, spectroscopic studies, and crystal structures of Boc-Leu-Lac-OEt and Boc-(Leu-Leu-Lac)(n)-OEt (n = 1, 2).	Depsipeptides	81-93	lactase	Homo sapiens	183-186
18234154-6	2008	Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells.	Depsipeptides	98-110	ATP binding cassette subfamily B member 1	Homo sapiens	43-46
17623797-0	2007	Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.	Depsipeptides	127-139	histone deacetylase 1	Homo sapiens	0-21
17610380-0	2007	Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.	Depsipeptides	0-12	BCR activator of RhoGEF and GTPase	Homo sapiens	57-60
17610380-2	2007	In this study, we report mechanisms of action of histone deacetylase (HDAC) inhibitor, depsipeptide (FK228) in BCR/ABL-expressing cell lines and its effectiveness in imatinib-resistant cells from patients with blast crisis of CML.	Depsipeptides	87-99	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	111-118
17186014-7	2007	Increased transgene expression following infection with an adenovirus expressing tumor necrosis factor-related apoptosis inducing ligand (TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275.	Depsipeptides	191-203	TNF superfamily member 10	Homo sapiens	81-136
17186014-7	2007	Increased transgene expression following infection with an adenovirus expressing tumor necrosis factor-related apoptosis inducing ligand (TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275.	Depsipeptides	191-203	TNF superfamily member 10	Homo sapiens	138-143
17240363-4	2007	We hypothesized that depsipeptide would modulate MMP-2 and MMP-9 production in lung adenocarcinoma cells line (A549).	Depsipeptides	21-33	matrix metallopeptidase 2	Homo sapiens	49-54
17240363-4	2007	We hypothesized that depsipeptide would modulate MMP-2 and MMP-9 production in lung adenocarcinoma cells line (A549).	Depsipeptides	21-33	matrix metallopeptidase 9	Homo sapiens	59-64
17240363-7	2007	RESULTS: The results showed that depsipeptide treatment decreased the expressions of MMP-2 and MMP-9 in dose-dependent manner.	Depsipeptides	33-45	matrix metallopeptidase 2	Homo sapiens	85-90
17240363-7	2007	RESULTS: The results showed that depsipeptide treatment decreased the expressions of MMP-2 and MMP-9 in dose-dependent manner.	Depsipeptides	33-45	matrix metallopeptidase 9	Homo sapiens	95-100
17240363-8	2007	The level of mRNA and proteins expressions were significantly decreased in depsipeptide treated A549 cells in a dose-dependent manner and the level of pro-MMP-9 was found to be high in the 100nm depsipeptide-treated cell lysate of A549 cells, suggesting inhibitory role of depsipeptide on pro-MMP-9 activation.	Depsipeptides	75-87	matrix metallopeptidase 9	Homo sapiens	155-160
17240363-8	2007	The level of mRNA and proteins expressions were significantly decreased in depsipeptide treated A549 cells in a dose-dependent manner and the level of pro-MMP-9 was found to be high in the 100nm depsipeptide-treated cell lysate of A549 cells, suggesting inhibitory role of depsipeptide on pro-MMP-9 activation.	Depsipeptides	75-87	matrix metallopeptidase 9	Homo sapiens	293-298
17240363-8	2007	The level of mRNA and proteins expressions were significantly decreased in depsipeptide treated A549 cells in a dose-dependent manner and the level of pro-MMP-9 was found to be high in the 100nm depsipeptide-treated cell lysate of A549 cells, suggesting inhibitory role of depsipeptide on pro-MMP-9 activation.	Depsipeptides	195-207	matrix metallopeptidase 9	Homo sapiens	155-160
17240363-8	2007	The level of mRNA and proteins expressions were significantly decreased in depsipeptide treated A549 cells in a dose-dependent manner and the level of pro-MMP-9 was found to be high in the 100nm depsipeptide-treated cell lysate of A549 cells, suggesting inhibitory role of depsipeptide on pro-MMP-9 activation.	Depsipeptides	195-207	matrix metallopeptidase 9	Homo sapiens	293-298
17240363-8	2007	The level of mRNA and proteins expressions were significantly decreased in depsipeptide treated A549 cells in a dose-dependent manner and the level of pro-MMP-9 was found to be high in the 100nm depsipeptide-treated cell lysate of A549 cells, suggesting inhibitory role of depsipeptide on pro-MMP-9 activation.	Depsipeptides	195-207	matrix metallopeptidase 9	Homo sapiens	155-160
17240363-8	2007	The level of mRNA and proteins expressions were significantly decreased in depsipeptide treated A549 cells in a dose-dependent manner and the level of pro-MMP-9 was found to be high in the 100nm depsipeptide-treated cell lysate of A549 cells, suggesting inhibitory role of depsipeptide on pro-MMP-9 activation.	Depsipeptides	195-207	matrix metallopeptidase 9	Homo sapiens	293-298
17240363-9	2007	Further immunocytochemistry studies showed the weak expression of MMP-2 and MMP-9 in depsipeptide treated cells.	Depsipeptides	85-97	matrix metallopeptidase 2	Homo sapiens	66-71
17240363-9	2007	Further immunocytochemistry studies showed the weak expression of MMP-2 and MMP-9 in depsipeptide treated cells.	Depsipeptides	85-97	matrix metallopeptidase 9	Homo sapiens	76-81
17240363-10	2007	CONCLUSION: We speculate that inhibition of metastasis-specific MMPs in cancer cells may be one of the targets for anticancer function of depsipeptide, and thus provides the molecular basis for the development of depsipeptide as a novel chemopreventive agent for metastatic lung cancer.	Depsipeptides	138-150	matrix metallopeptidase 2	Homo sapiens	64-68
17240363-10	2007	CONCLUSION: We speculate that inhibition of metastasis-specific MMPs in cancer cells may be one of the targets for anticancer function of depsipeptide, and thus provides the molecular basis for the development of depsipeptide as a novel chemopreventive agent for metastatic lung cancer.	Depsipeptides	213-225	matrix metallopeptidase 2	Homo sapiens	64-68
18639283-9	2008	Depsipeptide induced apoptosis in Caki-1, ACHN and 786O, and induced G2 cell cycle arrest in 769P.	Depsipeptides	0-12	La ribonucleoprotein 6, translational regulator	Homo sapiens	42-46
18185535-5	2008	First, by a quantitative assay of caspase-3/7 activity, a sublethal dose of depsipeptide was determined (ED50: 5 nM), in which p21(Waf1/Cip1) and Fas were sufficiently evoked concomitantly with histone H3 acetylation.	Depsipeptides	76-88	caspase 3	Mus musculus	34-43
18185535-5	2008	First, by a quantitative assay of caspase-3/7 activity, a sublethal dose of depsipeptide was determined (ED50: 5 nM), in which p21(Waf1/Cip1) and Fas were sufficiently evoked concomitantly with histone H3 acetylation.	Depsipeptides	76-88	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	127-130
18185535-5	2008	First, by a quantitative assay of caspase-3/7 activity, a sublethal dose of depsipeptide was determined (ED50: 5 nM), in which p21(Waf1/Cip1) and Fas were sufficiently evoked concomitantly with histone H3 acetylation.	Depsipeptides	76-88	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	131-135
18185535-5	2008	First, by a quantitative assay of caspase-3/7 activity, a sublethal dose of depsipeptide was determined (ED50: 5 nM), in which p21(Waf1/Cip1) and Fas were sufficiently evoked concomitantly with histone H3 acetylation.	Depsipeptides	76-88	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	136-140
17644301-0	2008	Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.	Depsipeptides	12-24	H3 histone pseudogene 16	Homo sapiens	155-158
18225533-0	2007	A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells.	Depsipeptides	26-38	growth arrest and DNA damage inducible beta	Homo sapiens	74-84
18225533-7	2007	A sequential treatment of depsipeptide+5-azacytidine (but not 5-azacytidine+depsipeptide) exhibited a synergistic effect on Gadd45beta gene reactivation in the HepG2 cells.	Depsipeptides	26-38	growth arrest and DNA damage inducible beta	Homo sapiens	124-134
17286952-3	2007	Histone deacetylase (HDAC) activity was inhibited by addition of the HDAC inhibitor depsipeptide to the culture medium for different exposure times.	Depsipeptides	84-96	histone deacetylase 9	Homo sapiens	0-19
17286952-3	2007	Histone deacetylase (HDAC) activity was inhibited by addition of the HDAC inhibitor depsipeptide to the culture medium for different exposure times.	Depsipeptides	84-96	histone deacetylase 9	Homo sapiens	21-25
17286952-3	2007	Histone deacetylase (HDAC) activity was inhibited by addition of the HDAC inhibitor depsipeptide to the culture medium for different exposure times.	Depsipeptides	84-96	histone deacetylase 9	Homo sapiens	69-73
17286952-6	2007	Detailed information was obtained for both the change of histone H4 acetylation specific to the N terminus and the global transformation of H4 from one acetylation state to another following treatment with the HDAC inhibitor depsipeptide.	Depsipeptides	225-237	histone deacetylase 9	Homo sapiens	210-214
17308048-2	2007	Previously, we showed that treatment with low doses of the histone deacetylase inhibitor FK228 (FR901228, depsipeptide) increased coxsackie adenovirus receptor (CAR) levels, histone H3 acetylation, and adenovirus infection efficiencies as measured by viral transgene expression in cancer cell lines but not in cultured normal cells.	Depsipeptides	106-118	coxsackie virus and adenovirus receptor	Mus musculus	161-164
16799637-3	2007	Here, we show that RUNX1-ETO undergoes degradation in response to treatment with histone deacetylase inhibitors, one of which, depsipeptide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies.	Depsipeptides	127-139	RUNX family transcription factor 1	Homo sapiens	19-24
16799637-3	2007	Here, we show that RUNX1-ETO undergoes degradation in response to treatment with histone deacetylase inhibitors, one of which, depsipeptide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies.	Depsipeptides	127-139	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	25-28
17064661-0	2006	5-Aza-2"-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer).	Depsipeptides	27-39	BCL2 interacting killer	Homo sapiens	77-80
17109024-3	2007	Notably, the pleiotropic HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and depsipeptide, have shown efficacy in a wide range of cancers, in particular for cutaneous T-cell lymphoma (CTCL), and are progressing in phase II clinical studies.	Depsipeptides	85-97	TSPY like 2	Homo sapiens	192-196
17064661-0	2006	5-Aza-2"-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer).	Depsipeptides	27-39	BCL2 interacting killer	Homo sapiens	82-105
17064661-6	2006	Histone acetylation of the BIK promoter region increased with depsipeptide treatment but was not further affected by 5-aza-2"-deoxycytidine.	Depsipeptides	62-74	BCL2 interacting killer	Homo sapiens	27-30
17064661-7	2006	In summary, synergistic upregulation of pro-apoptotic BIK-previously shown to suppress tumor growth-appears to play a critical role in anticancer effects of 5-aza-2"-deoxycytidine plus depsipeptide.	Depsipeptides	185-197	BCL2 interacting killer	Homo sapiens	54-57
16995669-1	2006	Fungal beauveriolide III (BeauIII, 1b), a cyclodepsipeptide inhibiting acyl-CoA:cholesterol acyltransferase (ACAT) and showing antiatherogenic activity in mouse models, consists of L-Phe, L-Ala, D-allo-Ile, and 3-hydroxy-4-methyloctanoic acid (HMA) moieties, but the stereochemistry of the HMA part has not until now been fully defined.	Depsipeptides	42-59	sterol O-acyltransferase 2	Mus musculus	109-113
16533780-0	2006	Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).	Depsipeptides	118-130	ATP binding cassette subfamily B member 1	Homo sapiens	10-14
16951199-3	2006	Epigenetic modifiers such as histone deacetylase inhibitor FK228 (depsipeptide) have been shown to increase CAR expression as well as the uptake of adenovirus in bladder cancer in vivo and in vitro, indicating that altered transcriptional regulation of CAR is the key mechanism responsible for the decreased CAR levels in this cancer.	Depsipeptides	66-78	CXADR Ig-like cell adhesion molecule	Homo sapiens	108-111
16951199-3	2006	Epigenetic modifiers such as histone deacetylase inhibitor FK228 (depsipeptide) have been shown to increase CAR expression as well as the uptake of adenovirus in bladder cancer in vivo and in vitro, indicating that altered transcriptional regulation of CAR is the key mechanism responsible for the decreased CAR levels in this cancer.	Depsipeptides	66-78	CXADR Ig-like cell adhesion molecule	Homo sapiens	253-256
16951199-3	2006	Epigenetic modifiers such as histone deacetylase inhibitor FK228 (depsipeptide) have been shown to increase CAR expression as well as the uptake of adenovirus in bladder cancer in vivo and in vitro, indicating that altered transcriptional regulation of CAR is the key mechanism responsible for the decreased CAR levels in this cancer.	Depsipeptides	66-78	CXADR Ig-like cell adhesion molecule	Homo sapiens	253-256
16537920-0	2006	Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).	Depsipeptides	74-86	tumor protein p53	Homo sapiens	15-18
16537920-0	2006	Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).	Depsipeptides	74-86	cyclin dependent kinase inhibitor 1A	Homo sapiens	109-112
16537920-0	2006	Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).	Depsipeptides	74-86	cyclin dependent kinase inhibitor 1A	Homo sapiens	113-117
16537920-0	2006	Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).	Depsipeptides	74-86	cyclin dependent kinase inhibitor 1A	Homo sapiens	118-122
16537920-2	2006	Here we found that an inhibitor of HDAC, depsipeptide (FR901228), but not trichostatin A (TSA), induces p21(Waf1/Cip1) expression through both p53 and Sp1/Sp3 pathways in A549 cells (which retain wild-type p53).	Depsipeptides	41-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	104-107
16537920-2	2006	Here we found that an inhibitor of HDAC, depsipeptide (FR901228), but not trichostatin A (TSA), induces p21(Waf1/Cip1) expression through both p53 and Sp1/Sp3 pathways in A549 cells (which retain wild-type p53).	Depsipeptides	41-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	108-112
16537920-2	2006	Here we found that an inhibitor of HDAC, depsipeptide (FR901228), but not trichostatin A (TSA), induces p21(Waf1/Cip1) expression through both p53 and Sp1/Sp3 pathways in A549 cells (which retain wild-type p53).	Depsipeptides	41-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	113-117
16537920-2	2006	Here we found that an inhibitor of HDAC, depsipeptide (FR901228), but not trichostatin A (TSA), induces p21(Waf1/Cip1) expression through both p53 and Sp1/Sp3 pathways in A549 cells (which retain wild-type p53).	Depsipeptides	41-53	tumor protein p53	Homo sapiens	143-146
16537920-2	2006	Here we found that an inhibitor of HDAC, depsipeptide (FR901228), but not trichostatin A (TSA), induces p21(Waf1/Cip1) expression through both p53 and Sp1/Sp3 pathways in A549 cells (which retain wild-type p53).	Depsipeptides	41-53	Sp3 transcription factor	Homo sapiens	155-158
16537920-2	2006	Here we found that an inhibitor of HDAC, depsipeptide (FR901228), but not trichostatin A (TSA), induces p21(Waf1/Cip1) expression through both p53 and Sp1/Sp3 pathways in A549 cells (which retain wild-type p53).	Depsipeptides	41-53	tumor protein p53	Homo sapiens	206-209
16537920-8	2006	Furthermore, activity associated with the binding of the acetylated p53 at K373/K382 to the p21 promoter as well as p21(Waf1/Cip1) expression is significantly increased after depsipeptide treatment, as tested by chromatin immunoprecipitations and Western blotting, respectively.	Depsipeptides	175-187	tumor protein p53	Homo sapiens	68-71
16537920-8	2006	Furthermore, activity associated with the binding of the acetylated p53 at K373/K382 to the p21 promoter as well as p21(Waf1/Cip1) expression is significantly increased after depsipeptide treatment, as tested by chromatin immunoprecipitations and Western blotting, respectively.	Depsipeptides	175-187	cyclin dependent kinase inhibitor 1A	Homo sapiens	92-95
16537920-8	2006	Furthermore, activity associated with the binding of the acetylated p53 at K373/K382 to the p21 promoter as well as p21(Waf1/Cip1) expression is significantly increased after depsipeptide treatment, as tested by chromatin immunoprecipitations and Western blotting, respectively.	Depsipeptides	175-187	cyclin dependent kinase inhibitor 1A	Homo sapiens	116-119
16537920-8	2006	Furthermore, activity associated with the binding of the acetylated p53 at K373/K382 to the p21 promoter as well as p21(Waf1/Cip1) expression is significantly increased after depsipeptide treatment, as tested by chromatin immunoprecipitations and Western blotting, respectively.	Depsipeptides	175-187	cyclin dependent kinase inhibitor 1A	Homo sapiens	120-124
16537920-8	2006	Furthermore, activity associated with the binding of the acetylated p53 at K373/K382 to the p21 promoter as well as p21(Waf1/Cip1) expression is significantly increased after depsipeptide treatment, as tested by chromatin immunoprecipitations and Western blotting, respectively.	Depsipeptides	175-187	cyclin dependent kinase inhibitor 1A	Homo sapiens	125-129
16537920-9	2006	In addition, p53 acetylation at K373/K382 is confirmed to be required for recruitment of p300 to the p21 promoter, and the depsipeptide-induced p53 acetylation at K373/K382 is unlikely to be dependent on p53 phosphorylation at Ser15, Ser20, and Ser392 sites.	Depsipeptides	123-135	tumor protein p53	Homo sapiens	13-16
16537920-9	2006	In addition, p53 acetylation at K373/K382 is confirmed to be required for recruitment of p300 to the p21 promoter, and the depsipeptide-induced p53 acetylation at K373/K382 is unlikely to be dependent on p53 phosphorylation at Ser15, Ser20, and Ser392 sites.	Depsipeptides	123-135	E1A binding protein p300	Homo sapiens	89-93
16537920-9	2006	In addition, p53 acetylation at K373/K382 is confirmed to be required for recruitment of p300 to the p21 promoter, and the depsipeptide-induced p53 acetylation at K373/K382 is unlikely to be dependent on p53 phosphorylation at Ser15, Ser20, and Ser392 sites.	Depsipeptides	123-135	cyclin dependent kinase inhibitor 1A	Homo sapiens	101-104
16537920-9	2006	In addition, p53 acetylation at K373/K382 is confirmed to be required for recruitment of p300 to the p21 promoter, and the depsipeptide-induced p53 acetylation at K373/K382 is unlikely to be dependent on p53 phosphorylation at Ser15, Ser20, and Ser392 sites.	Depsipeptides	123-135	tumor protein p53	Homo sapiens	144-147
16537920-9	2006	In addition, p53 acetylation at K373/K382 is confirmed to be required for recruitment of p300 to the p21 promoter, and the depsipeptide-induced p53 acetylation at K373/K382 is unlikely to be dependent on p53 phosphorylation at Ser15, Ser20, and Ser392 sites.	Depsipeptides	123-135	tumor protein p53	Homo sapiens	144-147
16537920-10	2006	Our data suggest that p53 acetylation at K373/K382 plays an important role in depsipeptide-induced p21(Waf1/Cip1) expression.	Depsipeptides	78-90	tumor protein p53	Homo sapiens	22-25
16537920-10	2006	Our data suggest that p53 acetylation at K373/K382 plays an important role in depsipeptide-induced p21(Waf1/Cip1) expression.	Depsipeptides	78-90	cyclin dependent kinase inhibitor 1A	Homo sapiens	99-102
16537920-10	2006	Our data suggest that p53 acetylation at K373/K382 plays an important role in depsipeptide-induced p21(Waf1/Cip1) expression.	Depsipeptides	78-90	cyclin dependent kinase inhibitor 1A	Homo sapiens	103-107
16537920-10	2006	Our data suggest that p53 acetylation at K373/K382 plays an important role in depsipeptide-induced p21(Waf1/Cip1) expression.	Depsipeptides	78-90	cyclin dependent kinase inhibitor 1A	Homo sapiens	108-112
16891247-0	2006	In vitro metabolism of the epoxide substructure of cryptophycins by cytosolic glutathione S-transferase: species differences and stereoselectivity.	Depsipeptides	51-64	glutathione S-transferase kappa 1	Homo sapiens	78-103
16849582-0	2006	Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.	Depsipeptides	15-27	TNF superfamily member 10	Homo sapiens	48-103
16260035-4	2006	P-gp expression returned to the parental cell level when resistant cells were cultured in depsipeptide-free medium, while resistant cells cultured in the medium containing 16 nM depsipeptide still showed hyper-acetylation of histones.	Depsipeptides	90-102	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
16260035-8	2006	Among the 28 genes that were upregulated, 15 genes also showed an increased expression in parental cells treated with 4 nM depsipeptide for 48 h, while the other 13 genes including P-gp were different.	Depsipeptides	123-135	ATP binding cassette subfamily B member 1	Homo sapiens	181-185
16260035-10	2006	These findings suggest that continuous exposure to depsipeptide reversibly induces P-gp, which contributes to the onset of resistance, but the altered gene expression profile of resistant cells may also play a role.	Depsipeptides	51-63	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
16533780-7	2006	We next examined MDR1 levels in normal and malignant PBMCs obtained from 15 patients enrolled in clinical trials with depsipeptide and detected up to a 6-fold increase in normal PBMCs and up to an 8-fold increase in circulating tumor cells after depsipeptide administration.	Depsipeptides	118-130	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
16533780-7	2006	We next examined MDR1 levels in normal and malignant PBMCs obtained from 15 patients enrolled in clinical trials with depsipeptide and detected up to a 6-fold increase in normal PBMCs and up to an 8-fold increase in circulating tumor cells after depsipeptide administration.	Depsipeptides	246-258	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
16533780-9	2006	These studies suggest that depsipeptide induces its own mechanism of resistance and thus provide a basis for clinical trials evaluating depsipeptide in combination with a Pgp inhibitor.	Depsipeptides	27-39	ATP binding cassette subfamily B member 1	Homo sapiens	171-174
16533780-2	2006	Because depsipeptide (FR901228, FK228, NSC630176) is a substrate for Pgp, up-regulation of the gene that encodes it, MDR1, would mean that depsipeptide induces its own mechanism of resistance.	Depsipeptides	8-20	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
16533780-2	2006	Because depsipeptide (FR901228, FK228, NSC630176) is a substrate for Pgp, up-regulation of the gene that encodes it, MDR1, would mean that depsipeptide induces its own mechanism of resistance.	Depsipeptides	8-20	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
15735751-0	2005	Sequential 5-Aza 2"-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.	Depsipeptides	34-46	tissue factor pathway inhibitor 2	Homo sapiens	71-104
16676400-7	2006	To study the mechanism of NNMT gene repression by depsipeptide, effects of depsipeptide on NNMT promoter activity were determined by luciferase reporter gene assay.	Depsipeptides	50-62	nicotinamide N-methyltransferase	Homo sapiens	26-30
16676400-7	2006	To study the mechanism of NNMT gene repression by depsipeptide, effects of depsipeptide on NNMT promoter activity were determined by luciferase reporter gene assay.	Depsipeptides	75-87	nicotinamide N-methyltransferase	Homo sapiens	91-95
16271139-7	2005	Inducible expression and function of the leukemia inhibitory factor receptor was assessed by treatment with the histone deacetylase inhibitor depsipeptide.	Depsipeptides	142-154	LIF receptor subunit alpha	Homo sapiens	41-76
15515013-0	2005	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).	Depsipeptides	135-147	tumor necrosis factor	Homo sapiens	19-40
15515013-0	2005	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).	Depsipeptides	135-147	tumor necrosis factor	Homo sapiens	42-45
15515013-0	2005	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).	Depsipeptides	135-147	tumor necrosis factor	Homo sapiens	47-50
15515013-0	2005	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).	Depsipeptides	135-147	histone deacetylase 9	Homo sapiens	105-124
15515013-2	2005	In this study, we conducted a detailed analysis of anti-leukemic effects of an HDAC inhibitor (HDI), depsipeptide (FK228), using myeloid leukemia cell lines HL-60 and K562.	Depsipeptides	101-113	histone deacetylase 9	Homo sapiens	79-83
15515013-3	2005	DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.	Depsipeptides	149-161	tumor necrosis factor	Homo sapiens	43-52
15515013-3	2005	DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.	Depsipeptides	149-161	tumor necrosis factor	Homo sapiens	43-46
15515013-3	2005	DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.	Depsipeptides	149-161	TNF receptor associated factor 6	Homo sapiens	118-124
15515013-3	2005	DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.	Depsipeptides	149-161	caspase 10	Homo sapiens	126-145
15515013-3	2005	DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.	Depsipeptides	149-161	tumor necrosis factor	Homo sapiens	96-99
15515013-3	2005	DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.	Depsipeptides	149-161	tumor necrosis factor	Homo sapiens	96-99
15515013-4	2005	Upregulation of TNF-alpha was induced by depsipeptide in HL-60 and K562 cells, which expressed type I TNF receptors (TNF-RI).	Depsipeptides	41-53	tumor necrosis factor	Homo sapiens	16-25
15515013-4	2005	Upregulation of TNF-alpha was induced by depsipeptide in HL-60 and K562 cells, which expressed type I TNF receptors (TNF-RI).	Depsipeptides	41-53	tumor necrosis factor	Homo sapiens	16-19
15515013-4	2005	Upregulation of TNF-alpha was induced by depsipeptide in HL-60 and K562 cells, which expressed type I TNF receptors (TNF-RI).	Depsipeptides	41-53	TNF receptor superfamily member 1A	Homo sapiens	117-123
15515013-5	2005	Depsipeptide activated caspases-8 and -10, which in turn cleave caspases-3 and -7, leading to apoptotic cell death in both cell lines.	Depsipeptides	0-12	caspase 8	Homo sapiens	23-41
15515013-5	2005	Depsipeptide activated caspases-8 and -10, which in turn cleave caspases-3 and -7, leading to apoptotic cell death in both cell lines.	Depsipeptides	0-12	caspase 3	Homo sapiens	64-81
15515013-7	2005	Finally, we demonstrated that the enhanced production of TNF-alpha by depsipeptide was due to transcriptional activation of the TNF-alpha gene through hyperacetylation of histones H3 and H4 in its promoter region (-208 to +35).	Depsipeptides	70-82	tumor necrosis factor	Homo sapiens	57-66
15515013-7	2005	Finally, we demonstrated that the enhanced production of TNF-alpha by depsipeptide was due to transcriptional activation of the TNF-alpha gene through hyperacetylation of histones H3 and H4 in its promoter region (-208 to +35).	Depsipeptides	70-82	tumor necrosis factor	Homo sapiens	128-137
15515013-8	2005	These results suggest that autocrine production of TNF-alpha plays a role in the cytotoxicity of depsipeptide against a subset of leukemias.	Depsipeptides	97-109	tumor necrosis factor	Homo sapiens	51-60
15771957-0	2005	Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.	Depsipeptides	0-12	TNF superfamily member 10	Homo sapiens	59-64
15771957-0	2005	Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.	Depsipeptides	0-12	TNF superfamily member 10	Homo sapiens	83-88
15771957-5	2005	Thus, studies were initiated to evaluate the ability of depsipeptide to enhance the cytotoxic activity of Ad5-TRAIL against human prostate tumor cells.	Depsipeptides	56-68	Alzheimer disease, familial, type 5	Homo sapiens	106-109
15771957-5	2005	Thus, studies were initiated to evaluate the ability of depsipeptide to enhance the cytotoxic activity of Ad5-TRAIL against human prostate tumor cells.	Depsipeptides	56-68	TNF superfamily member 10	Homo sapiens	110-115
15771957-7	2005	Additionally, tumor cell killing by Ad5-TRAIL was higher following depsipeptide pretreatment.	Depsipeptides	67-79	Alzheimer disease, familial, type 5	Homo sapiens	36-39
15771957-7	2005	Additionally, tumor cell killing by Ad5-TRAIL was higher following depsipeptide pretreatment.	Depsipeptides	67-79	TNF superfamily member 10	Homo sapiens	40-45
15771957-9	2005	Investigation into the mechanism responsible for increased TRAIL responsiveness revealed increased levels of TRAIL-R1 and -R2 in membrane lipid rafts following depsipeptide treatment.	Depsipeptides	160-172	TNF superfamily member 10	Homo sapiens	59-64
15771957-9	2005	Investigation into the mechanism responsible for increased TRAIL responsiveness revealed increased levels of TRAIL-R1 and -R2 in membrane lipid rafts following depsipeptide treatment.	Depsipeptides	160-172	TNF receptor superfamily member 10a	Homo sapiens	109-125
15771957-10	2005	These results indicate that depsipeptide is a potent agent for enhancing the activity of Ad5-TRAIL by multiple mechanisms, allowing for a more efficient use of Ad5-TRAIL as an antitumor therapy.	Depsipeptides	28-40	Alzheimer disease, familial, type 5	Homo sapiens	89-92
15771957-10	2005	These results indicate that depsipeptide is a potent agent for enhancing the activity of Ad5-TRAIL by multiple mechanisms, allowing for a more efficient use of Ad5-TRAIL as an antitumor therapy.	Depsipeptides	28-40	TNF superfamily member 10	Homo sapiens	93-98
15771957-10	2005	These results indicate that depsipeptide is a potent agent for enhancing the activity of Ad5-TRAIL by multiple mechanisms, allowing for a more efficient use of Ad5-TRAIL as an antitumor therapy.	Depsipeptides	28-40	Alzheimer disease, familial, type 5	Homo sapiens	160-163
15771957-10	2005	These results indicate that depsipeptide is a potent agent for enhancing the activity of Ad5-TRAIL by multiple mechanisms, allowing for a more efficient use of Ad5-TRAIL as an antitumor therapy.	Depsipeptides	28-40	TNF superfamily member 10	Homo sapiens	164-169
16223781-0	2006	Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.	Depsipeptides	95-107	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
16223781-3	2006	The combination of ATRA and the novel histone deacetylase inhibitor (HDACI) depsipeptide (FK228) induced P-gp expression and prevented growth inhibition and apoptosis in NB4 APL cells subsequently exposed to doxorubicin (DOX).	Depsipeptides	76-88	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
16676400-0	2006	Histone deacetylase inhibitor depsipeptide represses nicotinamide N-methyltransferase and hepatocyte nuclear factor-1beta gene expression in human papillary thyroid cancer cells.	Depsipeptides	30-42	nicotinamide N-methyltransferase	Homo sapiens	53-85
16676400-0	2006	Histone deacetylase inhibitor depsipeptide represses nicotinamide N-methyltransferase and hepatocyte nuclear factor-1beta gene expression in human papillary thyroid cancer cells.	Depsipeptides	30-42	HNF1 homeobox B	Homo sapiens	90-121
16676400-3	2006	In this work, we studied the effects of depsipeptide, a histone deacetylase inhibitor, on NNMT gene expression in BHP 18-21 papillary thyroid cancer cells.	Depsipeptides	40-52	nicotinamide N-methyltransferase	Homo sapiens	90-94
16676400-6	2006	NNMT protein level determined by Western blot analysis and NNMT catalytic activity was also reduced significantly in the depsipeptide-treated cells.	Depsipeptides	121-133	nicotinamide N-methyltransferase	Homo sapiens	0-4
16676400-6	2006	NNMT protein level determined by Western blot analysis and NNMT catalytic activity was also reduced significantly in the depsipeptide-treated cells.	Depsipeptides	121-133	nicotinamide N-methyltransferase	Homo sapiens	59-63
16424655-0	2006	Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.	Depsipeptides	30-42	histone deacetylase 9	Homo sapiens	0-19
16424655-0	2006	Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.	Depsipeptides	30-42	BCL2 associated X, apoptosis regulator	Homo sapiens	134-137
16424655-2	2006	In this study, we investigated the mechanisms of cytotoxic effects of depsipeptide (FK228), one of the most effective HDAC inhibitors against leukemia, using human myeloid leukemic cell lines HL-60 and K562.	Depsipeptides	70-82	histone deacetylase 9	Homo sapiens	118-122
16140944-6	2005	Quantitative reverse transcription-PCR analysis revealed robust, coincident induction of BORIS and NY-ESO-1 expression in lung cancer cells, but not normal human bronchial epithelial cells following 5-aza-2"-deoxycytidine (5-azadC), Depsipeptide FK228 (DP), or sequential 5-azadC/DP exposure under clinically relevant conditions.	Depsipeptides	233-245	CCCTC-binding factor like	Homo sapiens	89-94
16140944-6	2005	Quantitative reverse transcription-PCR analysis revealed robust, coincident induction of BORIS and NY-ESO-1 expression in lung cancer cells, but not normal human bronchial epithelial cells following 5-aza-2"-deoxycytidine (5-azadC), Depsipeptide FK228 (DP), or sequential 5-azadC/DP exposure under clinically relevant conditions.	Depsipeptides	233-245	cancer/testis antigen 1A	Homo sapiens	99-107
15735751-0	2005	Sequential 5-Aza 2"-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.	Depsipeptides	34-46	tissue factor pathway inhibitor 2	Homo sapiens	106-112
15735013-6	2005	Furthermore, RUNX1/MTG8 and DNMT1 were concurrently released from the IL-3 promoter by exposure to depsipeptide or stabilized on the promoter by decitabine treatment.	Depsipeptides	99-111	interleukin 3	Homo sapiens	70-74
15738394-6	2005	APAF-1, a gene central to the intrinsic apoptotic pathway, was induced by SAHA and depsipeptide and shown to be important, but not essential, for HDACi-induced cell death.	Depsipeptides	83-95	apoptotic peptidase activating factor 1	Homo sapiens	0-6
15735013-6	2005	Furthermore, RUNX1/MTG8 and DNMT1 were concurrently released from the IL-3 promoter by exposure to depsipeptide or stabilized on the promoter by decitabine treatment.	Depsipeptides	99-111	RUNX family transcription factor 1	Homo sapiens	13-18
15735013-6	2005	Furthermore, RUNX1/MTG8 and DNMT1 were concurrently released from the IL-3 promoter by exposure to depsipeptide or stabilized on the promoter by decitabine treatment.	Depsipeptides	99-111	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	19-23
15735013-6	2005	Furthermore, RUNX1/MTG8 and DNMT1 were concurrently released from the IL-3 promoter by exposure to depsipeptide or stabilized on the promoter by decitabine treatment.	Depsipeptides	99-111	DNA methyltransferase 1	Homo sapiens	28-33
14996704-4	2004	Treatment with depsipeptide, as well as other histone deacetylase inhibitors, caused induction of histone acetylation, induction of p21 expression, and substantial apoptosis without significant cell cycle arrest.	Depsipeptides	15-27	H3 histone pseudogene 16	Homo sapiens	132-135
15608694-4	2004	We report that low concentrations of histone deacetylase (HDAC) inhibitors, such as depsipeptide, which alone failed to induce apoptosis, markedly sensitize CLL cells and other primary lymphoid malignancies to TRAIL-induced apoptosis.	Depsipeptides	84-96	TNF superfamily member 10	Homo sapiens	210-215
15467034-11	2004	Depsipeptide-mediated apoptosis was associated with a 12-fold increased level of active caspase 3, but some apoptosis persisted despite z-VAD-fmk treatment to inhibit caspase activity.	Depsipeptides	0-12	caspase 3	Homo sapiens	88-97
14996704-6	2004	Treatment with depsipeptide increased expression of the interleukin-2 (IL-2) receptor, and combination with the IL-2 toxin conjugate denileukin diftitox resulted in more than additive toxicity.	Depsipeptides	15-27	interleukin 2	Homo sapiens	56-69
14996704-6	2004	Treatment with depsipeptide increased expression of the interleukin-2 (IL-2) receptor, and combination with the IL-2 toxin conjugate denileukin diftitox resulted in more than additive toxicity.	Depsipeptides	15-27	interleukin 2 receptor subunit beta	Homo sapiens	71-85
14996704-6	2004	Treatment with depsipeptide increased expression of the interleukin-2 (IL-2) receptor, and combination with the IL-2 toxin conjugate denileukin diftitox resulted in more than additive toxicity.	Depsipeptides	15-27	interleukin 2	Homo sapiens	71-75
14996704-8	2004	However, cells selected for resistance to depsipeptide in the presence of a Pgp inhibitor had a Pgp-independent mechanism of resistance.	Depsipeptides	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	76-79
14996704-8	2004	However, cells selected for resistance to depsipeptide in the presence of a Pgp inhibitor had a Pgp-independent mechanism of resistance.	Depsipeptides	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	96-99
15059137-3	2004	Depsipeptide, a new member of the HDAC inhibitors, was found to be safe in humans and has been shown to induce apoptosis in various cancers.	Depsipeptides	0-12	histone deacetylase 9	Homo sapiens	34-38
15109660-1	2004	Two analogues possessing steric hindered substituents on C-15 of arenastatin A (1), a potent cytotoxic spongean depsipeptide, were synthesized and shown to enhance stability in mouse serum.	Depsipeptides	112-124	placenta associated 8	Homo sapiens	57-61
15078940-2	2004	FR901228, FK228, or depsipeptide, is an HDAC inhibitor effective in T-cell lymphomas.	Depsipeptides	20-32	histone deacetylase 9	Homo sapiens	40-44
15059137-9	2004	BCL-2, BCL-XL and MCL-1 showed decreased expression in depsipeptide-treated samples.	Depsipeptides	55-67	BCL2 apoptosis regulator	Homo sapiens	0-5
15059137-9	2004	BCL-2, BCL-XL and MCL-1 showed decreased expression in depsipeptide-treated samples.	Depsipeptides	55-67	BCL2 like 1	Homo sapiens	7-13
15059137-9	2004	BCL-2, BCL-XL and MCL-1 showed decreased expression in depsipeptide-treated samples.	Depsipeptides	55-67	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-23
15014036-0	2004	Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.	Depsipeptides	54-66	cyclin dependent kinase inhibitor 1A	Homo sapiens	14-17
15014036-11	2004	Calphostin C abrogated p21 induction mediated by DP and enhanced DP-mediated apoptosis in a manner comparable with FLA in MPM cells; in contrast, phorbol-12,13-dibutyrate blocked FLA-mediated inhibition of p21 induction by DP and markedly protected these cells from the apoptotic effects of sequential DP/FLA.	Depsipeptides	49-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	23-26
15014036-8	2004	The proapoptotic effects of DP/FLA treatment coincided with inhibition of DP-mediated induction of p21 by FLA. Overexpression of p21 by adenoviral gene transfer techniques rendered MPM cells refractory to the cytotoxic effects of this treatment regimen.	Depsipeptides	28-30	cyclin dependent kinase inhibitor 1A	Homo sapiens	99-102
15014036-12	2004	CONCLUSIONS: FLA abrogates DP-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of DP in MPM cells.	Depsipeptides	27-29	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-55
15014036-8	2004	The proapoptotic effects of DP/FLA treatment coincided with inhibition of DP-mediated induction of p21 by FLA. Overexpression of p21 by adenoviral gene transfer techniques rendered MPM cells refractory to the cytotoxic effects of this treatment regimen.	Depsipeptides	28-30	cyclin dependent kinase inhibitor 1A	Homo sapiens	129-132
15014036-9	2004	In p21 reporter assays, promoter activation by DP was antagonized by FLA.	Depsipeptides	47-49	cyclin dependent kinase inhibitor 1A	Homo sapiens	3-6
15148683-5	2004	This review gives an overview of the occurrence and importance of beta2-amino acids in nature, placing emphasis on the metabolic pathways of beta-aminoisobutyric acid (beta-Aib) and the appearance of beta2-amino acids as secondary metabolites or as components of more complex natural products, such as peptides, depsipeptides, lactones, and alkaloids.	Depsipeptides	312-325	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	66-71
15148683-5	2004	This review gives an overview of the occurrence and importance of beta2-amino acids in nature, placing emphasis on the metabolic pathways of beta-aminoisobutyric acid (beta-Aib) and the appearance of beta2-amino acids as secondary metabolites or as components of more complex natural products, such as peptides, depsipeptides, lactones, and alkaloids.	Depsipeptides	312-325	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	200-205
15264661-1	2004	Poly(ester amide) copolymers based on L-lactide (2) and a new depsipeptide (1) were prepared by ring opening polymerization in the presence of Sn(Oct)2 as the catalyst.	Depsipeptides	62-74	POU domain, class 2, transcription factor 2	Mus musculus	143-151
14698558-10	2004	These results were validated in primary leukemia cells from patients with refractory or relapsed AML or chronic lymphocytic leukemia (CLL) treated on a Phase I clinical trial of the HDAC inhibitor depsipeptide.	Depsipeptides	197-209	histone deacetylase 9	Homo sapiens	182-186
14695142-7	2003	HRK expression was restored by treatment with a methyltransferase inhibitor, 5-aza-deoxycytidine, and enhanced further by addition of histone deacetylase inhibitor trichostatin A or depsipeptide.	Depsipeptides	182-194	harakiri, BCL2 interacting protein	Homo sapiens	0-3
15171260-2	2004	A number of structural classes of HDAC inhibitors have been developed of which several are in clinical trials, including phenylbutyrate (PB) and related compounds; the hydroxamic acids, suberoylanilide hydroxamic acid (SAHA) and depsipeptide (FK-228); and the benzamides, MS-275 and C1-994.	Depsipeptides	229-241	histone deacetylase 9	Homo sapiens	34-38
18521390-5	2004	Changes in CAR and alpha(v) integrin expression RMS in response to pretreatment with depsipeptide (FR901128) was determined using RT-PCR.Results.	Depsipeptides	85-97	CXADR Ig-like cell adhesion molecule	Homo sapiens	11-14
18521390-7	2004	RT-PCR analysis for CAR showed that in four of these five cell lines, CAR expression was increased 2.8-8.1-fold in cells treated with depsipeptide (FR901228) as compared to control.	Depsipeptides	134-146	CXADR Ig-like cell adhesion molecule	Homo sapiens	20-23
18521390-7	2004	RT-PCR analysis for CAR showed that in four of these five cell lines, CAR expression was increased 2.8-8.1-fold in cells treated with depsipeptide (FR901228) as compared to control.	Depsipeptides	134-146	CXADR Ig-like cell adhesion molecule	Homo sapiens	70-73
14528273-9	2003	Histone deacetylases (HDACs) can be inhibited by numerous compounds (sodium phenylbutyrate, valproic acid, novel compounds such as depsipeptide), which have entered the clinical arena in similar indications as Dnmt inhibitors.	Depsipeptides	131-143	DNA methyltransferase 1	Homo sapiens	210-214
12773551-9	2003	Depsipeptide induced p21(Cip1) expression was reconstituted when cells were pretreated with 5-aza-2"-deoxycytidine.	Depsipeptides	0-12	H3 histone pseudogene 16	Homo sapiens	21-24
12649137-0	2003	Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.	Depsipeptides	0-12	caspase 8	Homo sapiens	158-167
12649137-0	2003	Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.	Depsipeptides	0-12	CASP8 and FADD like apoptosis regulator	Homo sapiens	210-216
12649137-5	2003	Depsipeptide-induced apoptosis is caspase dependent, selectively involving the tumor necrosis factor (TNF) receptor (extrinsic pathway) initiating caspase 8 and effector caspase 3.	Depsipeptides	0-12	caspase 8	Homo sapiens	147-156
12782595-2	2003	In this work, we show that p21(WAF1) induction by HDAC inhibitors (depsipeptide and trichostatin A) is defective in Ataxia telangiectasia (AT) cells but normal in matched wild-type (WT) cells (human diploid fibroblasts).	Depsipeptides	67-79	cyclin dependent kinase inhibitor 1A	Homo sapiens	27-30
12782595-2	2003	In this work, we show that p21(WAF1) induction by HDAC inhibitors (depsipeptide and trichostatin A) is defective in Ataxia telangiectasia (AT) cells but normal in matched wild-type (WT) cells (human diploid fibroblasts).	Depsipeptides	67-79	cyclin dependent kinase inhibitor 1A	Homo sapiens	31-35
12782595-2	2003	In this work, we show that p21(WAF1) induction by HDAC inhibitors (depsipeptide and trichostatin A) is defective in Ataxia telangiectasia (AT) cells but normal in matched wild-type (WT) cells (human diploid fibroblasts).	Depsipeptides	67-79	histone deacetylase 9	Homo sapiens	50-54
12773551-9	2003	Depsipeptide induced p21(Cip1) expression was reconstituted when cells were pretreated with 5-aza-2"-deoxycytidine.	Depsipeptides	0-12	cyclin dependent kinase inhibitor 1A	Homo sapiens	25-29
12678732-4	2002	In the class of HDAC inhibitors, now included a short-chain fatty acids, such as 4-phenylbutyrate and valporic acid, hydroxamic acids, such as suberoylanilide hydroxamic acid (SAHA), pyroxamide, trichostatin A, oxamflatin and CHAPSs, cyclic tetrapeptides, such as trapoxin, apicidin and depsipeptide-also known as FK-228 or FR 901228, and benzamides, such as MS-275.	Depsipeptides	287-299	histone deacetylase 9	Homo sapiens	16-20
12634613-0	2003	Interaction of 5-aza-2"-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.	Depsipeptides	42-54	stratifin	Homo sapiens	100-111
12634613-0	2003	Interaction of 5-aza-2"-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.	Depsipeptides	42-54	cadherin 1	Homo sapiens	113-123
12634613-0	2003	Interaction of 5-aza-2"-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.	Depsipeptides	42-54	TIMP metallopeptidase inhibitor 3	Homo sapiens	128-167
12455031-7	2003	Using semi-quantitative RT-PCR, we observed that 5-aza-2"-deoxycytidine in combination with depsipeptide produced a greater reactivation of both maspin and gelsolin as compared to each agent alone.	Depsipeptides	92-104	serpin family B member 5	Homo sapiens	145-151
12455031-7	2003	Using semi-quantitative RT-PCR, we observed that 5-aza-2"-deoxycytidine in combination with depsipeptide produced a greater reactivation of both maspin and gelsolin as compared to each agent alone.	Depsipeptides	92-104	gelsolin	Homo sapiens	156-164
12481415-2	2002	Here we show that the HDIs sodium butyrate (Bu), trichostatin A (TSA) and depsipeptide (FR901228) all induced p21, but only TSA and FR901228 caused mitotic arrest (in addition to arrest in G1 and G2).	Depsipeptides	74-86	H3 histone pseudogene 16	Homo sapiens	110-113
12115133-3	2002	The structure of an 11-residue peptide Boc-Val-Ala-Leu-Aib-Val-Ala-Leu-Aib-Val-Ala-Leu-OMe (2), analog of a which is an amide previously determined Lac-containing depsipeptide, Boc-Val-Ala-Leu-Aib-Val-Lac-Leu-Aib-Val-Ala-Leu-OMe I. L. Karle, C. Das, and P. Balaram, Biopolymers, Vol.	Depsipeptides	163-175	ANIB1	Homo sapiens	71-74
12115133-3	2002	The structure of an 11-residue peptide Boc-Val-Ala-Leu-Aib-Val-Ala-Leu-Aib-Val-Ala-Leu-OMe (2), analog of a which is an amide previously determined Lac-containing depsipeptide, Boc-Val-Ala-Leu-Aib-Val-Lac-Leu-Aib-Val-Ala-Leu-OMe I. L. Karle, C. Das, and P. Balaram, Biopolymers, Vol.	Depsipeptides	163-175	ANIB1	Homo sapiens	71-74
12115133-3	2002	The structure of an 11-residue peptide Boc-Val-Ala-Leu-Aib-Val-Ala-Leu-Aib-Val-Ala-Leu-OMe (2), analog of a which is an amide previously determined Lac-containing depsipeptide, Boc-Val-Ala-Leu-Aib-Val-Lac-Leu-Aib-Val-Ala-Leu-OMe I. L. Karle, C. Das, and P. Balaram, Biopolymers, Vol.	Depsipeptides	163-175	ANIB1	Homo sapiens	71-74
12771887-1	2003	OBJECTIVE: Treating cancer cells with depsipeptide, a novel antitumor agent currently in a phase II clinical trial, causes potent upregulation of p21/WAF1 expression and cell arrest at G1 and G2 checkpoints.	Depsipeptides	38-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	146-149
12771887-1	2003	OBJECTIVE: Treating cancer cells with depsipeptide, a novel antitumor agent currently in a phase II clinical trial, causes potent upregulation of p21/WAF1 expression and cell arrest at G1 and G2 checkpoints.	Depsipeptides	38-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	150-154
12771887-7	2003	RESULTS: Flavopiridol completely abolished depsipeptide-mediated dose-dependent upregulation of p21/WAF1 expression.	Depsipeptides	43-55	cyclin dependent kinase inhibitor 1A	Homo sapiens	96-99
12771887-7	2003	RESULTS: Flavopiridol completely abolished depsipeptide-mediated dose-dependent upregulation of p21/WAF1 expression.	Depsipeptides	43-55	cyclin dependent kinase inhibitor 1A	Homo sapiens	100-104
12592335-0	2003	Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.	Depsipeptides	0-12	RUNX family transcription factor 1	Homo sapiens	153-157
12592335-0	2003	Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.	Depsipeptides	0-12	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	158-161
12592335-2	2003	We hypothesized that depsipeptide (FR901228), a novel HDAC inhibitor evaluated in ongoing clinical trials, restores gene transcription and cell differentiation in AML1/ETO-positive cells.	Depsipeptides	21-33	RUNX family transcription factor 1	Homo sapiens	163-167
12592335-2	2003	We hypothesized that depsipeptide (FR901228), a novel HDAC inhibitor evaluated in ongoing clinical trials, restores gene transcription and cell differentiation in AML1/ETO-positive cells.	Depsipeptides	21-33	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	168-171
12592335-3	2003	A dose-dependent increase in H3 and H4 histone acetylation was noted in depsipeptide-treated AML1/ETO-positive Kasumi-1 cells and blasts from a patient with t(8;21) AML.	Depsipeptides	72-84	RUNX family transcription factor 1	Homo sapiens	93-97
12592335-3	2003	A dose-dependent increase in H3 and H4 histone acetylation was noted in depsipeptide-treated AML1/ETO-positive Kasumi-1 cells and blasts from a patient with t(8;21) AML.	Depsipeptides	72-84	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	98-101
12592335-6	2003	Notably, the activity of depsipeptide was enhanced by 5-aza-2"-deoxycytidine, a DNA methyltransferase inhibitor (DNMT).	Depsipeptides	25-37	DNA methyltransferase 1	Homo sapiens	80-111
12592335-6	2003	Notably, the activity of depsipeptide was enhanced by 5-aza-2"-deoxycytidine, a DNA methyltransferase inhibitor (DNMT).	Depsipeptides	25-37	DNA methyltransferase 1	Homo sapiens	113-117
12115133-3	2002	The structure of an 11-residue peptide Boc-Val-Ala-Leu-Aib-Val-Ala-Leu-Aib-Val-Ala-Leu-OMe (2), analog of a which is an amide previously determined Lac-containing depsipeptide, Boc-Val-Ala-Leu-Aib-Val-Lac-Leu-Aib-Val-Ala-Leu-OMe I. L. Karle, C. Das, and P. Balaram, Biopolymers, Vol.	Depsipeptides	163-175	ANIB1	Homo sapiens	55-58
11753657-8	2001	Depsipeptide, an inhibitor of histone deacetylase, acts synergistically with 5-Aza-CdR in inducing expression of p16(INK4a) and p19(INK4d).	Depsipeptides	0-12	cyclin dependent kinase inhibitor 2A	Homo sapiens	113-116
11753657-8	2001	Depsipeptide, an inhibitor of histone deacetylase, acts synergistically with 5-Aza-CdR in inducing expression of p16(INK4a) and p19(INK4d).	Depsipeptides	0-12	cyclin dependent kinase inhibitor 2A	Homo sapiens	117-122
11753657-8	2001	Depsipeptide, an inhibitor of histone deacetylase, acts synergistically with 5-Aza-CdR in inducing expression of p16(INK4a) and p19(INK4d).	Depsipeptides	0-12	cyclin dependent kinase inhibitor 2D	Homo sapiens	128-131
11753657-8	2001	Depsipeptide, an inhibitor of histone deacetylase, acts synergistically with 5-Aza-CdR in inducing expression of p16(INK4a) and p19(INK4d).	Depsipeptides	0-12	cyclin dependent kinase inhibitor 2D	Homo sapiens	132-137
11753657-9	2001	However, when cells were treated with higher concentrations of 5-Aza-CdR and depsipeptide, p16(INK4a) expression was decreased together with significant suppression of cell growth.	Depsipeptides	77-89	cyclin dependent kinase inhibitor 2A	Homo sapiens	91-94
11753657-9	2001	However, when cells were treated with higher concentrations of 5-Aza-CdR and depsipeptide, p16(INK4a) expression was decreased together with significant suppression of cell growth.	Depsipeptides	77-89	cyclin dependent kinase inhibitor 2A	Homo sapiens	95-100
11753657-10	2001	Interestingly, p19(INK4d) expression was enhanced even more by the higher concentrations of 5-Aza-CdR and depsipeptide.	Depsipeptides	106-118	cyclin dependent kinase inhibitor 2D	Homo sapiens	15-18
11753657-10	2001	Interestingly, p19(INK4d) expression was enhanced even more by the higher concentrations of 5-Aza-CdR and depsipeptide.	Depsipeptides	106-118	cyclin dependent kinase inhibitor 2D	Homo sapiens	19-24
11472266-3	2001	The mechanism of anticancer activity of the cryptophycins has been associated with their destabilization of microtubules and with their induction of bcl-2 phosphorylation leading to apoptosis.	Depsipeptides	44-57	BCL2 apoptosis regulator	Homo sapiens	149-154
11592497-0	2001	SW-163C and E, novel antitumor depsipeptides produced by Streptomyces sp.	Depsipeptides	31-44	solute carrier family 9 (sodium/hydrogen exchanger), member 1	Mus musculus	0-13
11443220-0	2001	Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.	Depsipeptides	57-69	histone deacetylase 9	Homo sapiens	26-45
11443220-0	2001	Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.	Depsipeptides	57-69	solute carrier family 5 member 5	Homo sapiens	109-129
11443220-4	2001	We examined the ability of the novel histone deacetylase (HDAC) inhibitor, depsipeptide (FR901228), to modulate the expression of thyroid-specific genes.	Depsipeptides	75-87	histone deacetylase 9	Homo sapiens	37-56
11443220-4	2001	We examined the ability of the novel histone deacetylase (HDAC) inhibitor, depsipeptide (FR901228), to modulate the expression of thyroid-specific genes.	Depsipeptides	75-87	histone deacetylase 9	Homo sapiens	58-62
11443220-6	2001	In these four cell lines, a very low concentration of depsipeptide (1 ng/mL) increased histone acetylation and expression of both thyroglobulin and the Na(+)/I(-) symporter messenger RNAs.	Depsipeptides	54-66	solute carrier family 5 member 5	Homo sapiens	152-172
11443220-8	2001	Depsipeptide induced increases in (125)I accumulation indicated that a functional Na(+)/I(-) symporter protein was induced.	Depsipeptides	0-12	solute carrier family 5 member 5	Homo sapiens	82-102
8811880-6	1996	We have used the same principle to synthesize internally quenched depsipeptide fluorogenic substrates based on resonance energy transfer between the donor/acceptor couple 5-[(2"-aminoethyl)amino]naphthalene sulfonic acid/4-[[4"-(dimethylamino)phenyl]azo]benzoic acid, and developed a continuous assay for NS3 activity.	Depsipeptides	66-78	KRAS proto-oncogene, GTPase	Homo sapiens	305-308
11265773-3	2001	The authors designed the current study to determine whether the histone deacetylase inhibitor, depsipeptide FR901228 (DP), could enhance NY-ESO-1 induction mediated by the DNA demethylating agent 5-Aza-2"-deoxycytidine (DAC) in cell lines established primarily from thoracic cancers.	Depsipeptides	95-107	cancer/testis antigen 1A	Homo sapiens	137-145
11269744-13	2001	Thus, cryptophycins are potent inducers of Bcl-2 phosphorylation.	Depsipeptides	6-19	BCL2 apoptosis regulator	Homo sapiens	43-48
11269744-14	2001	The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality.	Depsipeptides	4-17	BCL2 apoptosis regulator	Homo sapiens	55-60
11269744-14	2001	The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality.	Depsipeptides	4-17	BCL2 apoptosis regulator	Homo sapiens	91-96
11269744-14	2001	The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality.	Depsipeptides	4-17	BCL2 apoptosis regulator	Homo sapiens	91-96
10091686-1	1999	Analogs of the antitumor agents cryptophycins 1 and 8 with dialkyl substitution at C-6 (fragment C) were synthesized and evaluated for in vitro cytotoxicity against human leukemia cells (CCRF-CEM).	Depsipeptides	32-45	complement C6	Homo sapiens	83-86
8980113-0	1996	Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins.	Depsipeptides	30-49	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
8980113-0	1996	Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins.	Depsipeptides	30-49	ATP binding cassette subfamily B member 4	Homo sapiens	101-105
8980113-4	1996	The human MDR1/Pgp conferred about 4-fold resistance to aureobasidin A, a cyclic depsipeptide antifungal antibiotic, on the drug-sensitive yeast strains.	Depsipeptides	81-93	ATP binding cassette subfamily B member 1	Homo sapiens	10-14
8980113-4	1996	The human MDR1/Pgp conferred about 4-fold resistance to aureobasidin A, a cyclic depsipeptide antifungal antibiotic, on the drug-sensitive yeast strains.	Depsipeptides	81-93	ATP binding cassette subfamily B member 1	Homo sapiens	15-18
7854121-2	1994	The vanX gene was located downstream from genes encoding the VanA ligase and the VanH dehydrogenase which synthesize the depsipeptide D-alanyl-D-lactate (D-Ala-D-Lac).	Depsipeptides	121-133	VanX	Enterococcus faecalis	4-8
34463219-0	2021	Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein.	Depsipeptides	14-26	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	103-108
8349413-7	1993	The possible use of Hib as an isosteric replacement for Aib in the design of conformationally constrained depsipeptides is briefly discussed.	Depsipeptides	106-119	ANIB1	Homo sapiens	56-59
1391633-0	1992	Crystal and molecular structure of the depsipeptide ionophore hexadecaisoleucinomycin, cyclo-[(D-Ile-L-Lac-L-Ile-D-Hyi)4-] (C80H136N8O24).	Depsipeptides	39-51	lactase	Homo sapiens	103-106
1391633-1	1992	The crystal structure of a synthetic depsipeptide ionophore hexadecaisoleucinomycin, cyclo [-(D-Ile-L-Lac-L-Ile-D-Hyi)4-] (C80H136N8O24), has been determined by single crystal x-ray diffraction techniques.	Depsipeptides	37-49	lactase	Homo sapiens	102-105
2386810-3	1990	Depsipeptide analogues of the repeating sequences of elastin in which this 4----1 hydrogen bond cannot exist were synthesized.	Depsipeptides	0-12	elastin	Homo sapiens	53-60
1724618-3	1990	The cyclic peptide microcystin-LR (MLR) and the depsipeptides, valinomycin (VLM) and enniatin-B (ENB), bind to CaM and inhibit PDE activity.	Depsipeptides	48-61	calmodulin 1	Homo sapiens	111-114
1510448-5	1992	VanY released the C-terminal D-hydroxy acid from depsipeptides produced by the vancomycin resistance protein VanA.	Depsipeptides	49-62	VanY protein	Enterococcus faecium	0-4
1510448-6	1992	These results demonstrate that VanY should contribute in vivo to the hydrolysis of both the D-alanyl-D-alanine- and the depsipeptide-containing peptidoglycan precursors.	Depsipeptides	120-132	VanY protein	Enterococcus faecium	31-35
915907-2	1977	A series of peptides and depsipeptides containing 2-methylcarbazic acid (H-Mec-OH), the 2-aza analogue of alanine, was prepared and tested as inhibitors of pancreatic and human granulocyte elastases.	Depsipeptides	25-38	C-C motif chemokine ligand 28	Homo sapiens	75-78
34141065-6	2021	Herein we describe our first efforts in natural product inhibitor discovery leading to the identification of a depsipeptide class of natural products as RNA-binding inhibitors of Dicer-mediated miRNA processing.	Depsipeptides	111-123	dicer 1, ribonuclease III	Homo sapiens	179-184
6654588-4	1983	Starting from Hyb-Phe-Pro-ONp (V) two epimeric N(3-hydroxybutyryl)diketopiperazines (VI) and (VII) and the corresponding 10-membered cyclodepsipeptide (VIII) could be isolated.	Depsipeptides	133-150	cytochrome c oxidase subunit 8A	Homo sapiens	152-156
4634303-0	1972	[Biological activity of peptide and depsipeptide analogs of ophthalmic and norophthalmic acids in glyoxalase I and formaldehyde:NAD-oxidoreductase enzyme systems].	Depsipeptides	36-48	glyoxalase I	Homo sapiens	98-110
32202785-0	2020	Design, Synthesis, and Conformation-Activity Study of Unnatural Bridged Bicyclic Depsipeptides as Highly Potent HIF-1 Inhibitors and Antitumor Agents.	Depsipeptides	81-94	hypoxia inducible factor 1 subunit alpha	Homo sapiens	112-117
33515365-4	2021	In the present work the effect of jasplakinolide, an actin-binding cyclodepsipeptide, on the SNTA1 protein activity and SNTA1 mediated downstream cellular events was studied in MDA-MB-231 breast cancer cell line.	Depsipeptides	67-84	syntrophin alpha 1	Homo sapiens	93-98
33639168-1	2021	Heterotrimeric G protein subunits Galphaq and Galpha11 are inhibited by two cyclic depsipeptides, FR900359 (FR) and YM-254890 (YM), both of which are being used widely to implicate Gq/11 proteins in the regulation of diverse biological processes.	Depsipeptides	76-96	G protein subunit alpha q	Homo sapiens	34-41
33639168-1	2021	Heterotrimeric G protein subunits Galphaq and Galpha11 are inhibited by two cyclic depsipeptides, FR900359 (FR) and YM-254890 (YM), both of which are being used widely to implicate Gq/11 proteins in the regulation of diverse biological processes.	Depsipeptides	76-96	G protein subunit alpha 11	Homo sapiens	46-54
28514117-5	2017	The suitability of the Ahp-cyclodepsipeptide scaffold for tailored inhibitor synthesis is showcased by the generation of the most potent human HTRA protease inhibitors to date.	Depsipeptides	27-44	HtrA serine peptidase 1	Homo sapiens	143-147
30909817-8	2020	Thus, the study revealed new depsipeptides as potential HDAC8 inhibitors.	Depsipeptides	29-42	histone deacetylase 8	Homo sapiens	56-61
31163697-2	2019	This natural 16-membered macrocyclic depsipeptide features an interesting side chain unit, namely 3-hydroxy-7-mercaptohept-4-enoic acid, which occurs in many other natural sulfur-containing HDAC inhibitors.	Depsipeptides	37-49	histone deacetylase 9	Homo sapiens	190-194
30212625-0	2018	Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.	Depsipeptides	0-13	kallikrein related peptidase 6	Homo sapiens	62-92
29265814-2	2018	The highly cytotoxic cyclodepsipeptides of the nannocystin family are known to bind to the eukaryotic translation elongation factor 1alpha (EF-1alpha).	Depsipeptides	21-39	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	140-149
29494533-0	2018	ATG5 Promotes Death Signaling in Response to the Cyclic Depsipeptides Coibamide A and Apratoxin A.	Depsipeptides	49-69	autophagy related 5	Mus musculus	0-4
30083689-0	2018	Chiral beta3-isocyanopropionates for multicomponent synthesis of peptides and depsipeptides containing a beta-amino acid fragment.	Depsipeptides	78-91	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	7-12
29235036-4	2018	Moreover, Alox15 expression was markedly upregulated by Class I HDAC inhibitors, MS-275 and depsipeptide.	Depsipeptides	92-104	arachidonate 15-lipoxygenase	Homo sapiens	10-16
28541699-2	2017	Kohamamides A, B, and C (1-3), new cyclic depsipeptides that belong to the kulolide superfamily, were isolated from an Okeania sp.	Depsipeptides	35-55	homeobox C13	Homo sapiens	0-28
27509880-2	2016	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.	Depsipeptides	64-76	histone deacetylase 9	Homo sapiens	81-85
27509880-0	2016	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.	Depsipeptides	49-61	histone deacetylase 9	Homo sapiens	19-38
27509880-0	2016	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.	Depsipeptides	49-61	H3 histone pseudogene 16	Homo sapiens	139-142
27509880-3	2016	Exposure to a combination of 5-FU (1.75 microM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7.	Depsipeptides	57-69	caspase 3	Homo sapiens	135-144
27509880-0	2016	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.	Depsipeptides	49-61	caspase 3	Homo sapiens	163-174
27509880-3	2016	Exposure to a combination of 5-FU (1.75 microM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7.	Depsipeptides	57-69	caspase 3	Homo sapiens	135-146
26036758-9	2015	Importantly, increasing FOXO1 acetylation by a HDAC inhibitor, depsipeptide, overcomes TKI resistance to effectively induce TKI-resistant NSCLC cell apoptosis.	Depsipeptides	63-75	forkhead box O1	Homo sapiens	24-29
27183222-2	2016	Pap-A is a cyclic depsipeptide that binds to PS in the membrane of wild-type Candida albicans, and permeabilizes its plasma membrane, ultimately causing cell death.	Depsipeptides	11-30	pappalysin 1	Homo sapiens	0-5
26625202-2	2016	The pan-HDAC inhibitors AR-42 and SAHA, and the class I HDAC inhibitor depsipeptide, suppressed mammosphere formation and other CSC markers by reducing Notch1 expression in MDA-MB-231 and SUM-159 cells.	Depsipeptides	71-83	histone deacetylase 9	Homo sapiens	56-60
26625202-2	2016	The pan-HDAC inhibitors AR-42 and SAHA, and the class I HDAC inhibitor depsipeptide, suppressed mammosphere formation and other CSC markers by reducing Notch1 expression in MDA-MB-231 and SUM-159 cells.	Depsipeptides	71-83	notch receptor 1	Homo sapiens	152-158
27020600-1	2016	Beauveriolides I and III, which are naturally occurring cyclodepsipeptides, have been reported to bind to sterol O-acyltransferase (SOAT), inhibiting its ability to synthesize cholesteryl esters.	Depsipeptides	56-74	sterol O-acyltransferase 1	Homo sapiens	106-130
27020600-1	2016	Beauveriolides I and III, which are naturally occurring cyclodepsipeptides, have been reported to bind to sterol O-acyltransferase (SOAT), inhibiting its ability to synthesize cholesteryl esters.	Depsipeptides	56-74	sterol O-acyltransferase 1	Homo sapiens	132-136
24438145-0	2014	Depsipeptide and roxithromycin induce apoptosis of lymphoma cells by blocking extracellular signal-regulated kinase activation.	Depsipeptides	0-12	mitogen-activated protein kinase 1	Mus musculus	78-115
25721083-6	2015	Other HDAC inhibitors, including trichostatin A, sodium butyrate, and depsipeptide, also activated IGF-1R signaling in vorinostat-resistant NSCLC cells.	Depsipeptides	70-82	insulin like growth factor 1 receptor	Homo sapiens	99-105
25128875-2	2014	Therefore a sensitive and specific bioanalytical high-throughput UHPLC-MS/MS method was developed for the quantitative and simultaneous determination of cyclic depsipeptide mycotoxins beauvericin and enniatins (A, A1, B, B1, D, E, C/F) in human skin Franz diffusion cell samples.	Depsipeptides	153-172	immunoglobulin kappa variable 2D-30	Homo sapiens	214-234
22748705-1	2012	The linear depsipeptide grassystatin A, a valuable probe for the study of cathepsin E function, has been synthesized by a [4+6] strategy.	Depsipeptides	11-23	cathepsin E	Homo sapiens	74-85
23894374-2	2013	In fact, two histone deacetylase inhibitors (HDIs), SAHA and Depsipeptide, are FDA approved for single-agent treatment of refractory cutaneous T cell lymphoma (CTCL).	Depsipeptides	61-73	TSPY like 2	Homo sapiens	160-164
23989727-2	2013	The antimycin-type depsipeptides are one such grouping, with a significant level of diversity and members that have noted activities against key targets governing human cellular apoptosis (e.g. Bcl-xL and GRP78).	Depsipeptides	19-32	BCL2 like 1	Homo sapiens	194-200
23989727-2	2013	The antimycin-type depsipeptides are one such grouping, with a significant level of diversity and members that have noted activities against key targets governing human cellular apoptosis (e.g. Bcl-xL and GRP78).	Depsipeptides	19-32	heat shock protein family A (Hsp70) member 5	Homo sapiens	205-210
24900634-3	2013	Here, we describe the design and preparation of a series of PYY(3-36) depsipeptide analogues, in which backbone amide-to-ester modifications were systematically introduced in the C-terminal.	Depsipeptides	70-82	peptide YY	Homo sapiens	60-63
21855532-0	2011	Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide.	Depsipeptides	127-139	glutathione S-transferase pi 1	Homo sapiens	0-30
22112863-5	2012	Depsipeptide induced oxidative stress was confirmed to relate to a disturbance in reduction-oxidation (redox) reactions through inhibition of the transactivation of thioredoxin reductase (TrxR) in human cancer cells.	Depsipeptides	0-12	peroxiredoxin 5	Homo sapiens	165-186
22112863-5	2012	Depsipeptide induced oxidative stress was confirmed to relate to a disturbance in reduction-oxidation (redox) reactions through inhibition of the transactivation of thioredoxin reductase (TrxR) in human cancer cells.	Depsipeptides	0-12	peroxiredoxin 5	Homo sapiens	188-192
22112863-6	2012	Upon treatment with depsipeptide, p53 phosphorylation at threonine 18 (Thr18) was specifically induced.	Depsipeptides	20-32	tumor protein p53	Homo sapiens	34-37
22112863-8	2012	Our results demonstrate that depsipeptide plays an anti-neoplastic role by generating ROS to elicit p53/p21 pathway activation.	Depsipeptides	29-41	tumor protein p53	Homo sapiens	100-103
22112863-8	2012	Our results demonstrate that depsipeptide plays an anti-neoplastic role by generating ROS to elicit p53/p21 pathway activation.	Depsipeptides	29-41	H3 histone pseudogene 16	Homo sapiens	104-107
21987446-0	2011	The seminoma cell line TCam-2 is sensitive to HDAC inhibitor depsipeptide but tolerates various other chemotherapeutic drugs and loss of NANOG expression.	Depsipeptides	61-73	histone deacetylase 9	Homo sapiens	46-50
21987446-6	2011	Here, we treated the seminoma-like cell line TCam-2 with the HDAC-inhibitor Depsipeptide, the global demethylating agent 5-aza-2"-deocycytidine, all-trans retinoic acid and the monaminooxidase inhibitor Tranylcipromine and also used knock down approaches to reduce expression of the pluripotency marker NANOG and/or the inhibitor of primordial germ cell differentiation TFAP2C.	Depsipeptides	76-88	histone deacetylase 9	Homo sapiens	61-65
21362133-7	2011	In fact, two actively studied HDAC inhibitors, vorinostat and depsipeptide, were recently approved for the treatment of refractory cutaneous T cell lymphoma.	Depsipeptides	62-74	histone deacetylase 9	Homo sapiens	30-34
21705224-6	2011	The porpoisamides are a unique pair of cyclic depsipeptides that are epimeric at C-2 of the beta-amino acid, 3-amino-2-methyloctanoic acid.	Depsipeptides	39-59	complement C2	Homo sapiens	81-84
21855532-0	2011	Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide.	Depsipeptides	127-139	glutathione S-transferase pi 1	Homo sapiens	31-36
21855532-3	2011	We chose the GSTP1 gene which is silenced by hypermethylation to analyze the effect of the histone deacetylase inhibitor depsipeptide on DNA methylation and histone modifications at the GSTP1 promoter site.	Depsipeptides	121-133	glutathione S-transferase pi 1	Homo sapiens	186-191
20361469-6	2010	In fact, vorinostat and depsipeptide, two actively studied HDAC inhibitors, were recently approved for the treatment of refractory cutaneous T-cell lymphoma.	Depsipeptides	24-36	histone deacetylase 9	Homo sapiens	59-63
20811718-5	2010	In addition, we found that the combination of 30 microM zebularine and 6 or 7 nM depsipeptide resulted in a synergistic inhibition of cell growth in tumor cells with silenced CDKN2A (p<0.001, CI=0.70 and 0.57, respectively) but not in tumor cells with deleted CDKN2A.	Depsipeptides	81-93	cyclin dependent kinase inhibitor 2A	Homo sapiens	175-181
20811718-5	2010	In addition, we found that the combination of 30 microM zebularine and 6 or 7 nM depsipeptide resulted in a synergistic inhibition of cell growth in tumor cells with silenced CDKN2A (p<0.001, CI=0.70 and 0.57, respectively) but not in tumor cells with deleted CDKN2A.	Depsipeptides	81-93	cyclin dependent kinase inhibitor 2A	Homo sapiens	263-269
21879444-5	2011	Recently, the two HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, Vorinostat) and Romidepsin (Depsipeptide, FK228) were FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL).	Depsipeptides	101-113	TSPY like 2	Homo sapiens	188-192
20811699-0	2010	Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.	Depsipeptides	49-61	H2A.X variant histone	Mus musculus	123-127
20811699-0	2010	Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.	Depsipeptides	49-61	transformation related protein 53, pseudogene	Mus musculus	148-151
20811699-2	2010	The present study showed that the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and depsipeptide (FK228) synergistically enhanced ionizing radiation (IR)-induced apoptosis, associated with activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase in Y79 and WER1-Rb1 human retinoblastoma cells.	Depsipeptides	96-108	caspase 3	Homo sapiens	215-224
20811699-2	2010	The present study showed that the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and depsipeptide (FK228) synergistically enhanced ionizing radiation (IR)-induced apoptosis, associated with activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase in Y79 and WER1-Rb1 human retinoblastoma cells.	Depsipeptides	96-108	poly(ADP-ribose) polymerase 1	Homo sapiens	241-268
19233470-5	2009	It is shown that depsipeptide is effective at submicromolar concentrations and acts mainly by apoptosis induction, upregulation of p21 and cell cycle inhibition in G2/M.	Depsipeptides	17-29	H3 histone pseudogene 16	Homo sapiens	131-134
19233470-7	2009	In summary, depsipeptide induced protein acetylation results in transcriptional changes of a large number of pathogenetically relevant genes and increased RelA/p65 binding activity in cHL cell lines.	Depsipeptides	12-24	RELA proto-oncogene, NF-kB subunit	Homo sapiens	155-159
19233470-7	2009	In summary, depsipeptide induced protein acetylation results in transcriptional changes of a large number of pathogenetically relevant genes and increased RelA/p65 binding activity in cHL cell lines.	Depsipeptides	12-24	RELA proto-oncogene, NF-kB subunit	Homo sapiens	160-163